Amborse cell therapy

What Amborse cell therapy does

Ambrose Cell Therapy is a private, for-profit cell therapy company founded in 2018 by Matthew (Matt) Feshbach. Headquartered in Tampa, Florida, the company delivers autologous adipose-derived stem and regenerative cell (ADRC) therapy to US patients with life-threatening and debilitating chronic conditions who have exhausted conventional treatment options ('no-option' patients), operating under the legal framework of the Federal Right to Try Act of 2017. The company treats a broad indication menu including autoimmune disease, orthopedics, neurological conditions, neuropathy, diabetes, kidney disease, inflammatory bowel disease, men's health, and spinal cord injury.

The core technology stack centers on the Celution System (manufactured by Lorem Cytori, San Diego, CA), a closed, sterile point-of-care device used to liberate ADRCs from a patient's own adipose tissue. Published studies cited by the company report that Celution produces the highest ADRC yield, viability, and purity of any adipose cell processing device, and the same system has been used in 9 FDA-approved trials at institutions including Cedars-Sinai, Stanford, and the Texas Heart Institute, supported by 80+ peer-reviewed human studies and a 125,000+ paper scientific literature base. Treatments are delivered by a team of five physicians plus support staff at the AAAAHC-accredited Salus ambulatory surgery center in Beverly Hills, CA.

The business model is direct-to-consumer, professional-services revenue from patient treatment fees. Pricing is not publicly disclosed; patients must complete a candidacy evaluation before being quoted costs. Demand generation is built on multilingual educational content (8 languages) and patient-reported outcomes rather than paid celebrity or social media marketing, a positioning the company explicitly contrasts against other domestic and offshore stem cell clinics. There are no disclosed funding rounds, institutional investors, or revenue figures; the company appears to be bootstrapped and founder-controlled since inception.

Name

Amborse cell therapy

Legal name

Ambrose Cell Therapy

Website

https://ambrosecelltherapy.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Ambrose Cell Therapy is a private Beverly Hills-based clinic that delivers autologous adipose-derived stem and regenerative cell (ADRC) therapy to US 'no-option' patients with chronic, debilitating conditions under the Federal Right to Try Act, using the Celution System at an AAAAHC-accredited surgery center.

Ownership category

akta.pro rank

Product category

Regenerative Medicine / Cell Therapy Services

NAICS

Blood and Organ Banks (621991)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Cell Therapy Developers (Autologous) (HLAAABAA)

akta.pro secondary industries

Stem Cell Therapies (MSC/iPSC/HSC-derived) (HLAAABAE), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Regenerative cell therapy
• Autologous stem cell treatment
• Adipose-derived regenerative cells
• Right to try therapies
• Chronic disease cell therapy

Headquarters

HQ city

Tampa

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure, Supply Chain

Revenue model

1. Cell Therapy Treatment Services: Ambrose provides personalized cell therapy treatment plans and cycles of care based on patient needs and goals. The protocol includes fat harvesting, ADRC preparation, and personalized treatment delivery in an AAAAHC-accredited surgery center. Revenue is generated through patient treatment fees.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Ambrose Cell Therapy provides personalized autologous adipose-derived stem and regenerative cell (ADRC) therapy to patients with life-threatening or debilitating conditions who have exhausted conventional medical options. Treatment is delivered under the Federal Right to Try Act of 2017 and includes fat harvesting, ADRC processing via the Celution System, and regenerative injections performed by board-certified specialists at an AAAAHC-accredited ambulatory surgery center in Beverly Hills, CA. The company serves as a direct-to-consumer cell therapy center of excellence, distinguishing itself from celebrity-promoted offshore stem cell clinics through a science-led, educational content strategy.

Product overview

Ambrose Cell Therapy operates as a single, unified cell therapy service rather than a software platform. The core offering is their autologous adipose-derived stem and regenerative cell (ADRC) treatment, which uses the Celution System to process fat tissue and deliver personalized regenerative injections. The protocol includes fat harvesting, ADRC preparation using the Celution System, and a personalized treatment plan delivered in an AAAAHC-accredited surgery center. No software products, modules, or add-on services are offered.

Differentiator

Problem solved

Functional benefit

Products and services

• Ambrose Cell Therapy (Autologous ADRC Treatment) Personalized autologous adipose-derived stem and regenerative cell (ADRC) therapy delivered under the Federal Right to Try Act of 2017 to US patients with life-threatening or debilitating conditions who have exhausted conventional medical options. The protocol includes fat harvesting (liposuction), ADRC processing via the Celution System, and personalized regenerative injections performed by board-certified specialists at the AAAAHC-accredited Salus ASC in Beverly Hills, CA.

Quantifiable outcome

• Patient testimonials report improvements in blood pressure, blood sugar, cholesterol, REM sleep, and mood comparable to levels not seen since patient's 20s (8 months post-treatment)
• +3 more outcomes

Named customers9 records

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Five partnerships are on record, tiered core and minor.

• Lorem CytoricoreTechnology or IntegrationLorem Cytori (San Diego, CA) provides the Celution System used by Ambrose to process adipose-derived stem and regenerative cells. Published studies confirm that Celution-processed output contains the highest ADRC yield, viability, and purity of any adipose cell processing device. The system is a closed, sterile technology validated in multiple FDA-approved trials.
• Salus ASCcoreStrategic or Co-development PartnerSalus ASC (ambulatory surgery center) is the AAAAHC-accredited facility where Ambrose provides cell therapy treatments. Located at 50 N. La Cienega Blvd, Suite 201, Beverly Hills, CA 90211, the center provides the surgical environment for fat harvesting and regenerative injections.
• Cedar-SinaiminorStrategic or Co-development PartnerCedar-Sinai Medical Center has utilized the Celution System in FDA-approved trials. Dr. Ram Dandillaya serves as Clinical Chief in the Division of Cardiology at Cedars-Sinai Medical Center and serves as Medical Director for Ambrose, reviewing patient clearances.
• Stanford UniversityminorStrategic or Co-development PartnerStanford University Medical Center has utilized the Celution System in FDA-approved trials. Dr. Nitesh Patel completed his interventional pain management fellowship at Stanford University Medical Center and serves as Attending Physician and Regenerative Injection Specialist at Ambrose.
• Texas Heart InstituteminorStrategic or Co-development PartnerTexas Heart Institute has utilized the Celution System in FDA-approved trials, contributing to the validation of ADRC safety and effectiveness in cardiac applications.

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Okyanos Cell Therapy: Founder Matt Feshbach's prior cell therapy practice in the Bahamas, operating the same ADRC protocols and 'no-option' patient criteria on the same Celution platform. Closest functional precedent to Ambrose's US model.
• Celltex Therapeutics: Houston-based adult stem cell therapy provider using autologous mesenchymal stem cell technology for chronic and degenerative conditions — same cash-pay, indication-driven regenerative medicine model with a focus on orthopedic and autoimmune diseases.
• GIOSTAR: Global Institute of Stem Cell Treatment and Research operates stem cell treatment centers offering autologous and allogeneic therapies for chronic conditions, frequently catering to US patients willing to travel for regenerative care.
• Personalized Stem Cells: US stem cell clinic operator pursuing FDA-regulated trials for autologous adipose-derived therapies — directly comparable autologous ADRC playbook, though operating under IND rather than Right to Try.
• StemGenex: California-based stem cell treatment center providing autologous cell-based therapies for chronic and degenerative conditions on a cash-pay, patient-direct basis.

Broad incumbents

• Regenexx: Larger US regenerative medicine network focused on orthopedic and musculoskeletal conditions using autologous cell therapies — overlaps with Ambrose's orthopedic focus area as a clinic operator and brand.

Emerging players

• BioRestorative Therapies: Public development-stage cell therapy company focused on autologous stem cell platforms for disc and metabolic disease — adjacent technology and indication overlap with Ambrose's orthopedic and chronic disease focus.

Regional players

• Dr. PRP USA: US regenerative medicine provider offering autologous platelet-rich plasma and cell-based therapies in a clinic setting — adjacent service model and target patient profile to Ambrose.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights5 records

Customer concentration

• Facebookfacebook.com/AmbroseCellTherapy
• LinkedInlinkedin.com/company/ambrose-cell-therapy

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amborse cell therapy